Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid entities : Regeneron pharmaceuticals, inc. save search
Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
Published: 2021-11-12 (Crawled : 15:30) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.66%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
covid europe antibody covid-19
New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Published: 2021-11-08 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 3.88%
H: 0.78%
C: 0.68%
covid casirivimab phase 3
FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.2%
H: 0.08%
C: -0.43%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.07%
H: 2.19%
C: 0.47%
covid treatment fda casirivimab fda acceptance
New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19
Published: 2021-09-30 (Crawled : 05:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid results casirivimab covid-19
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Published: 2021-09-29 (Crawled : 21:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid positive results casirivimab phase 3 trial trial results
UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection
Published: 2021-08-20 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.51%
H: 2.29%
C: 0.65%
covid antibody authorized injection covid-19 infections
Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
Published: 2021-07-20 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.29%
H: 1.02%
C: 0.78%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.52%
H: 0.92%
C: -0.18%
covid treatment antibody casirivimab
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
Published: 2021-06-16 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.15%
H: 0.3%
C: -0.78%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.7%
H: 2.12%
C: -1.43%
covid casirivimab phase 3 trial sars-cov-2
FDA Authorizes Lower 1,200 mg Intravenous and Subcutaneous Dose of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail to Treat Patients with COVID-19
Published: 2021-06-04 (Crawled : 12:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.79%
H: 0.55%
C: 0.19%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.38%
H: 2.12%
C: 0.85%
covid fda antibody casirivimab authorized
Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Published: 2021-05-17 (Crawled : 14:15) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.59%
H: 1.0%
C: 0.83%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.03%
H: 1.84%
C: 1.41%
covid risk casirivimab phase 3
Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19
Published: 2021-04-12 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.33%
H: 0.12%
C: -0.69%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -1.86%
covid treatment phase 3 trial casirivimab injection infections
NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression
Published: 2021-04-09 (Crawled : 13:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.18%
H: 0.79%
C: 0.57%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.03%
H: 0.85%
C: -0.22%
covid treatment risk casirivimab
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
Published: 2021-03-25 (Crawled : 13:15) - prnewswire.com
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.24%
H: 0.25%
C: -0.46%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.44%
H: 1.64%
C: 1.13%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -3.25%
H: 5.48%
C: 4.71%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 0.05%
H: 3.56%
C: 1.09%
covid vaccine research covid-19
Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Published: 2021-03-23 (Crawled : 07:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.2%
H: 0.22%
C: -1.32%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.61%
H: 0.53%
C: -3.37%
covid antibody phase 3 trial casirivimab
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
Published: 2021-03-12 (Crawled : 14:21) - prnewswire.com
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.8%
H: 1.16%
C: 0.77%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.63%
H: 1.03%
C: 0.96%
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -4.58%
H: 3.51%
C: 2.2%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: -3.18%
H: 3.97%
C: 3.97%
covid vaccine research covid-19
Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Published: 2021-02-25 (Crawled : 19:00) - biospace.com/
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 0.37%
H: 1.02%
C: -1.55%
covid phase 3 trial casirivimab
Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
Published: 2021-01-26 (Crawled : 13:00) - biospace.com/
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: -2.65%
covid positive antibody vaccine
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.